Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

Sara Kreimer,Wei Xue,Amira Qumseya,Timothy B. Lautz,Archana Shenoy,Susan Hiniker,Dana Casey,Rajkumar Venkatramani,Carola Arndt
DOI: https://doi.org/10.1002/pbc.31421
2024-11-08
Pediatric Blood & Cancer
Abstract:Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5‐year overall survival exceeds 70%. With more long‐term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5‐year event‐free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.
oncology,pediatrics,hematology
What problem does this paper attempt to address?